accueil

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London, and Milan, the firm brings together a team of over 45 professionals from all over Europe, the U.S., and Asia. 

The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed more than 500 companies throughout five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

Sofinnova Partners invest in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations. The firm invests in Life Sciences (Biopharmaceuticals, Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. The firm's partners sit on the boards of its portfolio companies and play an active role in the formation phase alongside entrepreneurs. Sofinnova Partners invests throughout Europe from its headquarters in Paris with a portion of investments made in the rest of the world.

View More

Alderley Park, 27 October 2020, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce that it has appointed Dr Jane Robertson as Chief Medical Officer.     Jane is a well respected UK hae...

October 22, 2020 12:30 AM Eastern Daylight Time   PARIS--BUSINESS WIRE --Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing in...

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The b...

Dr. Anderson’s appointment as Partner in the Crossover Fund reflects the venture capital firm’s continuing expansion across the entire value chain of life sciences investments, from seed to later-stage   PARIS, France – October 14, 2020 - Sofinnova Partners, a...

Designation based on positive topline results from NATIVE Phase IIb clinical trial evaluating lanifibranor in non-alcoholic steatohepatitis (NASH) Lanifibranor believed to be the first drug candidate to receive Breakthrough Therapy designation in NASH since 20...

Henrijette Richter

Henrijette Richter

Managing Partner

MEET OUR TEAM